Fundraising FoxThiel Capital — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
3T Biosciences3tbiosciences.comin𝕏Oct 2017
3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
K. Christopher GarciaMarvin Gee(Founder)in
Co-investorsAsset Management CompanyCollaborative FundCRV (Charles River Ventures)Westlake Village BioPartnersMenlo VenturesOS Fund+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.